Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00311402 |
Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily
Condition | Intervention | Phase |
---|---|---|
Cerebrovascular Accident |
Drug: Aggrenox capsule Drug: ASA 81 mg tablet |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Parallel Assignment |
Official Title: | JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-Release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily |
Estimated Enrollment: | 1250 |
Study Start Date: | April 2006 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with a diagnosis of cerebral infarction (excluding cardiogenic cerebral embolism) who meet the diagnostic criteria based on the National Institute of Neurological Disorders and Stroke (NINDS) ad hoc committee¿s classification of cerebrovascular disease III.
Patients who have at least two of the following risk factors:
Exclusion Criteria:
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
Study ID Numbers: | 9.178 |
Study First Received: | March 28, 2006 |
Last Updated: | April 22, 2009 |
ClinicalTrials.gov Identifier: | NCT00311402 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Anti-Inflammatory Agents Cerebral Infarction Cyclooxygenase Inhibitors Stroke Vascular Diseases Central Nervous System Diseases Fibrinolytic Agents Cardiovascular Agents Ischemia Brain Diseases Cerebrovascular Disorders Recurrence |
Fibrin Modulating Agents Aspirin Analgesics, Non-Narcotic Brain Ischemia Platelet Aggregation Inhibitors Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Brain Infarction Antirheumatic Agents Infarction Dipyridamole |
Anti-Inflammatory Agents Cerebral Infarction Molecular Mechanisms of Pharmacological Action Hematologic Agents Physiological Effects of Drugs Fibrinolytic Agents Brain Diseases Cerebrovascular Disorders Fibrin Modulating Agents Aspirin Sensory System Agents Therapeutic Uses Brain Ischemia Anti-Inflammatory Agents, Non-Steroidal Cardiovascular Diseases |
Analgesics Cyclooxygenase Inhibitors Nervous System Diseases Stroke Vascular Diseases Central Nervous System Diseases Enzyme Inhibitors Cardiovascular Agents Pharmacologic Actions Analgesics, Non-Narcotic Platelet Aggregation Inhibitors Brain Infarction Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |